Steven Shak, MD

Steven Shak, MD, chief Scientific Officer, Oncotype Dx, discusses the good news for patients with breast cancer emerging from the NCI-sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, trial.

The goal of the trial was to examine the effects of chemotherapy in patients with breast cancer who had a midrange recurrent score from 12 to 25. The analysis includes additional single gene results from patients with recurrence scores less than 11 who received hormonal therapy alone.

Videos

Shak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.

Steven Shak, MD | Authors

Articles

Dr. Steven Shak on the Results of the TAILORx Trial for Breast Cancer